How Hybrid Closed-Loop Pumps Like OmniPod 5 Are Changing Daily Life for People With Type 1 Diabetes

A hybrid closed-loop insulin pump is an automated system made up of three key parts: an insulin pump, a continuous glucose monitor (CGM), and a software algorithm that works together in real time. The CGM reads your blood sugar levels throughout the day. The algorithm uses this information to automatically tell the pump how much insulin to deliver. You still need to tell the system about meals and make adjustments, but the pump handles much of the minute-to-minute work that would otherwise require manual dosing.

For people with type 1 diabetes, this is a significant shift. As one Maryland teenager described after receiving an OmniPod 5 system, the technology means the pump can predict glucose patterns and adjust insulin delivery automatically, rather than requiring multiple daily injections or constant pump adjustments.

A large real-world study published in 2024 examined data from 69,902 OmniPod 5 users in the United States. Researchers looked at how well people maintained healthy glucose levels after they started using the system. The results were encouraging: users who set their average glucose target at 110 mg/dL spent a median of 68.8% of their time in the healthy target range of 70-180 mg/dL. For comparison, users with slightly higher glucose targets (120 mg/dL and 130-150 mg/dL) had lower time in range but still showed meaningful glucose control.

One important safety finding: across all users, the time spent with dangerously low blood sugar (below 70 mg/dL) was minimal—less than 1.13% of the time for all groups. This matters because severe hypoglycemia (low blood sugar) is a serious concern for many people with type 1 diabetes. Time in range improved for both children and adolescents and adults using the system.

Several hybrid closed-loop systems are now available, including OmniPod 5, Medtronic MiniMed 780G, Medtronic MiniMed 670G, Tandem Control-IQ, and others. A systematic review comparing these systems found that all of them significantly improved time in target glucose range compared to standard insulin therapy without continuous glucose monitoring.

However, the systems showed different levels of effectiveness. The Medtronic MiniMed 780G achieved the highest time in range in clinical trials, followed by Control-IQ and then OmniPod 5. All systems reduced dangerous low blood sugar episodes compared to standard therapy, with the largest reductions seen in certain systems. The takeaway: while all hybrid closed-loop systems offer benefits, the differences matter when making a treatment decision with your healthcare team.

Research is expanding into how hybrid closed-loop systems work in specific groups. A controlled trial of pregnant women with type 1 diabetes, published in 2023, found that those using hybrid closed-loop therapy spent significantly more time in the pregnancy-specific glucose target range (63-140 mg/dL) compared to standard therapy—a mean of 68.2% versus 55.6%. This matters because maintaining healthy glucose levels during pregnancy is critical for both mother and baby. The study also found that closed-loop users spent less time with high blood sugar during pregnancy.

For children, ongoing registries like the Post Market Registry for OmniPod 5 are actively collecting safety and effectiveness data in real-world conditions. These studies will help healthcare teams understand how well these systems work across different ages and how to optimize them for each person.

Hybrid closed-loop systems are now recommended by clinical guidelines as the preferred insulin delivery method for people with type 1 diabetes. However, access depends on individual circumstances, insurance coverage, and healthcare systems. The real-world evidence continues to grow as more people use these systems outside of research settings.

Multiple studies are underway to understand how hybrid closed-loop systems affect not only glucose control but also quality of life and mental health—called patient-reported outcomes. These studies in the United States and Europe will help answer questions about optimal settings, long-term safety, and which populations benefit most. If you're considering a hybrid closed-loop system, discussing the available options and your individual needs with your healthcare team is an important first step.

Origin: YouTube / WMDT News (Video report). Evidence: Video report, corroborated with 6 indexed studies. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.